Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
Date:11/7/2008

der the terms of the agreement, $1.0 million was paid upon execution of the agreement and the remaining $3.1 million was paid in September when we vacated our premises. We recognized in operating expense, the gain of $4.1 million and $116,867 of expense related to the new lease and our relocation to the new facility in September 2008.

Total operating expenses for the third quarter of 2008 were $(611,506), which included $4.0 million net lease termination gain, compared to $3.5 million in the same period in 2007. Total operating expenses decreased 55% to $4.2 million for the nine months ended September 30, 2008, from $9.4 million for the same period in 2007. The decreases in operating expenses were primarily due to the net gain of $4.0 million from the lease termination and surrender agreement associated with our corporate facility.

SCOLR had approximately $8.9 million in cash and cash equivalents, and $564,000 in restricted cash as of September 30, 2008. The Company is investing its cash and cash equivalents in government-backed securities.

Conference Call

As previously announced, SCOLR Pharma will host a conference call on November 7, 2008, at 11:30 a.m. (Eastern Standard Time). Shareholders and other interested parties may participate in the conference call by dialing +1- 888-713-4215 (domestic) or +1 617-213-4867 (international) and entering access code 67625263, a few minutes before 11:30 a.m. EST on November 7, 2008. The call will also be broadcast live on the Internet at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.

A replay of the conference call will be accessible two hours after its completion through November 21, 2008, by dialing +1-888-286-8010 (domestic) or +1 617-801-6888 (international) and entering access code 60696221.
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
3. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
4. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... According to Millennium Research Group (MRG), the global ... US minimally invasive spinal fusion market will expand ... 12% through 2014, reimbursement concerns in certain segments ... previously had been forecast at almost 20%. ,, ... Technologies 2010 report finds that ...
(Date:12/16/2009)... Accuray Incorporated (Nasdaq: ARAY ), a global leader ... president and chief executive officer, Euan S. Thomson, Ph.D., ... Morgan Healthcare Conference in San Francisco on Wednesday, January ... ,, A live webcast of each presentation will be ... Company,s Web site at http://www.accuray.com . The ...
(Date:12/16/2009)... HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) an ... $1 million in 12% per annum short term debt ... an initial drawdown of $500,000, with accrued interest and ... $500,000 with accrued interest and principal repayable in one ... becoming cashflow positive for any calendar month prior to ...
Breaking Medicine Technology:Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 2Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 3Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference 2HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2Rush Copley Medical Center Uses Thomson Reuters Order Sets Solution to Improve Joint Commission S3 Scores 56059 1Rush Copley Medical Center Uses Thomson Reuters Order Sets Solution to Improve Joint Commission S3 Scores 56059 2Rush Copley Medical Center Uses Thomson Reuters Order Sets Solution to Improve Joint Commission S3 Scores 56059 3Hologic to Present at the 2009 Morgan Stanley Global Healthcare Unplugged Conference 56056 1Lead Levels in Many Lipsticks Higher Than Reported 56053 1Lead Levels in Many Lipsticks Higher Than Reported 56053 2Lead Levels in Many Lipsticks Higher Than Reported 56053 3
... Nile Therapeutics,Inc. (Nasdaq: NLTX ), today announced ... placebo-controlled clinical study of CD-NP, a novel,chimeric natriuretic ... heart failure., The primary objective of the ... physiologic parameters of intravenous infusions of,CD-NP in patients ...
... Silence Therapeutics plc (AIM: SLN), a,leading European RNAi ... Pharmaceuticals Inc. ("Quark") together with Pfizer, has,commenced a ... small,interfering RNA (siRNA) therapeutic product based on Silence,s ... payment to,Silence from Quark., The study is ...
Other Medicine Technology:Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients 2Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients 3Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial 2Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial 3Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial 4
(Date:12/16/2009)... to Benefit of Children with Autism and Other Special ... and Zachary Levi Join Ben Stiller to Ring in ... At its 13th annual Teddy Bear Ball, ... President & CEO Brian Goldner received ... his far-reaching philanthropic leadership and commitment to children,s causes; ...
(Date:12/16/2009)... Losing has never felt so good for ... healthy new lifestyle means continuing to make smart choices ... milk is one healthy choice that is an important ... everyone can take. Every glass of milk has nine ... help maintain normal blood pressure, and calcium and vitamin ...
(Date:12/16/2009)... Dec. 16 HealthSciences Institute will ... care professionals, teams and organizations who serve ... chronic diseases in employer, health plan, medical ... collaborative will offer free, noncommercial webinars on ... disease prevention, management and care improvement. Each ...
(Date:12/16/2009)... advance that could help ease health and environmental concerns ... of technology for changing the behavior of nanoparticles in ... the environment. Their study was published in ACS, journal ... from the UK Centre for Ecology and Hydrology and ... production of nanoparticles particles less than 1/1000th the ...
(Date:12/16/2009)... cut bleeding time in half, but use in humans is ... Hoping to improve on nature, researchers have built and tested ... used in trauma or other cases where blood just won,t ... material that is used in degradable stitches, which dissolve in ... engineering at Case Western Reserve University, and lead author of ...
Breaking Medicine News(10 mins):Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Behavior modification could ease concerns about nanoparticles 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3
... BRITISH COLUMBIA, Canada, Jan. 13 InNexus ... http://www.ixsbio.com ), a drug development company commercializing the ... Cross Linking (DXL(TM)) technology, announces the completion of a ... its lead candidate DXL625 (CD20). The Company also ...
... Jan. 13 Gulf Coast,Veterinary Specialists (GCVS), one ... announced it will be installing the VIA(R) practice ... Medical Systems.,GCVS currently uses Eklin,s RapidStart(TM) DR (digital ... part of the,facility,s Eklin Digital Practice(R). All ...
... Jan. 13 In honor of its broad-based,efforts to ... its community,St. Mary,s Health System in Lewiston, Maine, is ... for Excellence in Community Service,one of the most esteemed ... Each year, this $100,000 prize is presented ...
... RALEIGH, N.C., Jan. 13 PRA International, a ... with LSK,Global Pharma Services and Mediscience Planning. ... PRA International), Mediscience and LSK,encompasses the joint management ... related services such as study monitoring and data ...
... physicians and community to assist individuals with ... Integrated, a pioneer in population health management, ... get the most medical and psychosocial support ... Connect(TM) service actively connects people to their ...
... Wire Seminars(TM) Celebrates 3 Decades of Orthodontic Continuing ... Wire Seminars , Inc., a leading provider of ... anniversary starting this month, January 2009. The ... by offering a wide array of courses and ...
Other Medicine News:Health News:InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA 2Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 2Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 3Health News:St. Mary's Health System in Maine Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 2Health News:St. Mary's Health System in Maine Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 3Health News:St. Mary's Health System in Maine Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 4Health News:St. Mary's Health System in Maine Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 5Health News:St. Mary's Health System in Maine Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 6Health News:PRA Expands Capabilities to Execute Multinational Trials in Asia 2Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 2Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 3Health News:Don't Trust Any Continuing Education Provider Under 30 2Health News:Don't Trust Any Continuing Education Provider Under 30 3
Corneal Trephine Punch - Stainless steel unit with titanium jaws, complete with PTFE cutting block. 1 reusable unit....
Corneal Marker - 8 blades, 2 sizes available: 7.0mm, 8.0mm. 1 piece per box...
... accuracy and control you've come to demand ... principles the BD K-4000 microkeratome is built ... real-time systems monitoring. The front panel on ... advanced ergonomics and bright visual feedback., ,The ...
... Cannulated Screw System is part ... systems developed by DePuy ACE ... 3.5mm to 8.0mm. Complete with ... system was designed with the ...
Medicine Products: